Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association

Bipolar Disorders

Volumn 16, Issue 2, 2014, Pages 199-203

  Ostacher, Michael J ^a   Iosifescu, Dan V ^b   Hay, Aleena ^c   Blumenthal, Sarah R ^d   Sklar, Pamela ^b   Perlis, Roy H ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bipolar disorder; Calcium channel antagonist; Depression; Dihydropyridine; Genome wide; Isradipine; L type calcium channel; Proof of concept

Indexed keywords

ISRADIPINE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; HUMAN; HYPOMANIA; MALE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PILOT STUDY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

BIPOLAR DISORDER; CALCIUM CHANNEL ANTAGONIST; DEPRESSION; DIHYDROPYRIDINE; GENOME-WIDE; ISRADIPINE; L-TYPE CALCIUM CHANNEL; PROOF-OF-CONCEPT;

ADULT; BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; ISRADIPINE; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 84896737158     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12143     Document Type: Article

References (20)

1. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009; 360: 1696-1698.
2. Collins FS. Reengineering translational science: the time is right. Sci Transl Med 2011; 3: 90.
3. Ferreira MA, O'Donovan MC, Meng YA et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40: 1056-1058.
4. Sklar P, Ripke S, Scott LJ et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011; 43: 977-983.
5. Cross-Disorder Group of the Psychiatric Genomics C, Smoller JW, Craddock N et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381: 1371-1379.
6. Casamassima F, Hay AC, Benedetti A, Lattanzi L, Cassano GB, Perlis RH. L-type calcium channels and psychiatric disorders: a brief review. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1373-1390.
7. Pazzaglia PJ, Post RM, Ketter TA et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998; 18: 404-413.
8. First MB, Spitzer R, Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders. New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 1996.
9. Dennehy EB, Bauer MS, Perlis RH, Kogan JN, Sachs GS. Concordance with treatment guidelines for bipolar disorder: data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacol Bull 2007; 40: 72-84.
10. Rush AJ, Trivedi MH, Ibrahim HM et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573-583.
11. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
12. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology: US Dept Health Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976: 218-222.
14. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986; 22: 343-381.
15. Fava M, Iosifescu DV, Pedrelli P, Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009; 78: 91-97.
16. Anonymous. Isradipine (Dynacirc) Package Insert. Available from: http://www.drugs.com/monograph/isradipine.html [accessed January 2013].
17. Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010; 87: 356-361.
18. Cohen C, Perrault G, Sanger DJ. Assessment of the antidepressant-like effects of L-type voltage-dependent channel modulators. Behav Pharmacol 1997; 8: 629-638.
19. Dao DT, Mahon PB, Cai X et al. Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry 2010; 68: 801-810.
20. Frye MA. Clinical practice. Bipolar disorder-a focus on depression. N Engl J Med 2011; 364: 51-59.